Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||

US9066980 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 4 months from now) | |

US8729094 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 4 months from now) | |

US9457020 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 4 months from now) | |

US8518981 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 4 months from now) | |

US9439854 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 4 months from now) | |

US7947725 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 4 months from now) | |

US8598218 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 4 months from now) | |

US9457021 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 4 months from now) | |

US9125905 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 4 months from now) | |

US7960424 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 4 months from now) | |

US9173942 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 4 months from now) | |

US7947724 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 4 months from now) | |

US8598219 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 4 months from now) | |

US7947724
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 9 months from now) | |

US7947725
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 9 months from now) | |

US7960424
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 9 months from now) | |

US8518981
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 9 months from now) | |

US8598218
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 9 months from now) | |

US9173942
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 9 months from now) | |

US9439854
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 9 months from now) | |

US9457020
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 9 months from now) | |

US8729094
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 9 months from now) | |

US8598219
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 9 months from now) | |

US9125905
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 9 months from now) | |

US9457021
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 9 months from now) | |

US9066980
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 9 months from now) |

Treatment: Prevention of chemotherapy-induced nausea and vomiting

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage

Strength | Dosage | Availability |
---|---|---|

EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) | INJECTABLE;INTRAVENOUS | Discontinued |

EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | INJECTABLE;INTRAVENOUS | Discontinued |

Click on the highlighted region to filter.